Table 4.
Model-based estimates for change over time in %-predicted forced vital capacity (n=138) and carbon monoxide diffusing capacity (n=99) in patients with systemic sclerosis by Scl-70 and WED (95% CI)*
| Change from baseline |
FVC | DLCO | ||||||
|---|---|---|---|---|---|---|---|---|
| Scl-70 Negative | Scl-70 Positive | Scl-70 Negative | Scl-70 Positive | |||||
| 1 year | 0.36 | (−0.1, 0.83) | −1.27 | (−2.0, −0.56) | −0.66 | (−1.3, −0.01) | −0.93 | (−2.2, 0.33) |
| 2 years | 0.71 | (−0.2, 1.66) | −2.53 | (−3.9, −1.12) | −1.32 | (−2.6, −0.02) | −1.86 | (−4.4, 0.66) |
| 3 years | 1.07 | (−0.4, 2.49) | −3.80 | (−5.9, −1.67) | −1.99 | (−3.9, -0.03) | −2.79 | (−6.6, 0.99) |
| 5 years | 1.78 | (−0.6, 4.15) | −6.33 | (−9.9, −2.79) | −3.31 | (−6.6, −0.05) | −4.65 | (−11.0, 1.65) |
| WED < 19mm | WED ≥ 19mm | WED < 19mm | WED ≥ 19mm | |||||
| 1 year | 0.14 | (−0.4, 0.68) | −0.49 | (−1.1, 0.11) | −0.43 | (−1.2, 0.34) | −1.12 | (−2.0, −0.23) |
| 2 years | 0.27 | (−0.8, 1.35) | −0.97 | (−2.2, 0.22) | −0.85 | (−2.4, 0.67) | −2.23 | (−4.0, −0.46) |
| 3 years | 0.41 | (−1.2, 2.03) | −1.46 | (−3.2, 0.33) | −1.28 | (−3.6, 1.01) | −3.35 | (−6.0, −0.69) |
| 5 years | 0.68 | (−2.0, 3.38) | −2.43 | (−5.4, 0.55) | −2.13 | (−5.9, 1.68) | −5.58 | (−10.0, −1.15) |
Scl-70 = anti-topoisomerase 1; FVC = forced vital capacity; DLCO = diffusing capacity for carbon monoxide (adjusted for hemoglobin); PFT = pulmonary function test. PFT results shown as %-predicted.
PFT means for Scl-70 analysis adjusted for sex, proton pump inhibitor use, prednisone use, SSc disease subtype, duration since first non-Raynaud (years), smoking history (current or former), and widest esophageal diameter. PFT means for WED analysis adjusted for sex, proton pump inhibitor use, prednisone use, SSc disease subtype, duration since first non-Raynaud (years), smoking history (current or former), and Scl-70 autoantibody status.